Laboratory Corporation of America Holdings

Fundamentals7.0
Price Action4.0
News Sentiment0.0
AI Rating
7.0

Key Drivers

  • Cash Flow
  • Margin Expansion
  • Debt Load

AI
AI Summary

7.0

Labcorp's improving specialty-testing mix, tighter health-system integration, and solid free cash flow make it a stronger long-term earnings story than the market is pricing in, but with valuation already fair and the chart still weak, the stock needs clean execution and a hold above key support to justify a re-rating.

GrowthOpportunity
ExecutionRisk
Valuation‍

Price Chart

Loading chart...

Financial Metrics

-
Revenue (TTM)
-
Net Income (TTM)
-
EPS (Q)
-
MCAP

Deep Analysis

Research tool. Not personalized advice.

Fundamental Analysis

7.0

Key Financial Insights:

  • Cash Flow
  • Margin Expansion
  • Debt Load

LH delivers steady margins, strong free cash flow, and manageable leverage, but its premium valuation and intangible-heavy balance sheet temper upside.

StableCashFlow
PremiumValuation

Price Behavior

4.0
Research tool. Not personalized advice. Technical analysis is for informational purposes only.

Key Price Behavior Insights:

  • Lower highs
  • Failed rebound
  • Support test

Over the last month, LH has been in a bearish downtrend with lower highs, repeated rejection at $257-$258, and $250 now the key support to watch.

bearish
technical
Support Level: $250
Resistance Level: $257-$258

Repeated failures to hold $257-$258 after the late-April peak, signaling weakening buying momentum

Sentiment & News

0.0

Key News Insights:

  • Q1 Beat
  • Raised Guidance
  • Epic Expansion

Labcorp delivered a strong Q1 beat with a raised 2026 outlook, while continued partnership and digital-integration wins reinforce improving momentum.

earnings
outlook

This news is positive for LH, as better-than-expected results and an improved outlook suggest solid operational momentum and support a constructive near-term view